title: Application of kinase bypass strategies to nucleoside antivirals.
abstract: Nucleoside and nucleotide analogs have served as the cornerstones of antiviral therapy for many viruses. However, the requirement for intracellular activation and side-effects caused by distribution to off-target sites of toxicity still limit the efficacy of the current generation of drugs. Kinase bypass strategies, where phosphorylated nucleosides are delivered directly into cells, thereby, removing the requirement for enzyme catalyzed phosphorylation steps, have already changed the face of antiviral therapy in the form of the acyclic nucleoside phosphonates, cidofovir, adefovir (given orally as its dipivoxil prodrug) and tenofovir (given orally as its disoproxil prodrug), currently used clinically. These strategies hold further promise to advance the field of antiviral therapy with at least 10 kinase bypass and tissue targeted prodrugs, representing seven distinct prodrug classes, currently in clinical trials. This article reviews the history of kinase bypass strategies applied to nucleoside antivirals and the evolution of different tissue targeted prodrug strategies, highlighting clinically relevant examples.
authors: Gilead Sciences, Inc., Foster City, CA 94404, USA. adrian.ray@gilead.com
authors: Adrian S
authors: AS
authors: Ray
authors: Karl Y
authors: KY
authors: Hostetler
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000266:history / Q000494:pharmacology* / Q000627:therapeutic use; D000077404:Cidofovir; D002986:Clinical Trials as Topic; D003596:Cytosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009705:Nucleosides / Q000266:history / Q000494:pharmacology* / Q000627:therapeutic use; D009711:Nucleotides / Q000266:history / Q000494:pharmacology* / Q000627:therapeutic use; D063065:Organophosphonates / Q000494:pharmacology / Q000627:therapeutic use; D010770:Phosphotransferases / Q000378:metabolism; D000068698:Tenofovir
chemical_list: D000998:Antiviral Agents; D009705:Nucleosides; D009711:Nucleotides; D063065:Organophosphonates; C053001:adefovir; D003596:Cytosine; D000068698:Tenofovir; D010770:Phosphotransferases; D000225:Adenine; D000077404:Cidofovir